Abstract: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
Abstract: Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
Abstract: In accordance with certain embodiments of the present disclosure, a kit is described. The kit includes primed living cells joined to and at least partially within a three-dimensional hydrogel structure and an isolated polypeptide having the carboxy-terminal amino acid sequence of an alpha Connexin, or a conservative variant thereof, wherein the polypeptide does not include the full length alpha Connexin protein.
Type:
Application
Filed:
October 1, 2010
Publication date:
April 14, 2011
Applicants:
Medical University of South Carolina, University of South Carolina
Abstract: Disclosed herein are methods and systems related to the body region analysis. In some forms, the analysis relates to body region abnormalities. In some forms, the methods and systems analyze and assign comparison scores (such as Z-score) to an image of a body region. In some forms, the comparison score is plotted voxel-by-voxel.
Abstract: Disclosed is a method for the anaerobic microbial dechlorination of polychlorinated biphenyls (PCBs). Polyhalogenated ethenes are used to stimulate the growth and dechlorinating activity of PCB dechlorinating bacteria in a contaminated soil or sediment. This method may be further coupled with aerobic microbial degradation of PCBs for the complete destruction of PCBs in soils and sediments. Polyhalogenated ethenes are also used in growth media for the culturing of PCB dechlorinating bacteria.
Type:
Grant
Filed:
February 3, 2003
Date of Patent:
December 9, 2008
Assignees:
University of Maryland Biotechnology Institute, Medical University of South Carolina
Abstract: Methods for determining whether the brain activity of a human subject in response to a stimulus of interest or question of interest is characteristic of a state of interest, such as a deceptive state or a truthful state, are disclosed. Some methods include the use of control questions, including truthful control questions and deceptive control questions, to provide bases for comparison for responses to stimuli of interest or questions of interest. Some methods include the use of differences between two states, such as a deceptive state and a truthful state. In some methods, brain maps are generated and compared. Also disclosed are systems for detecting deception by measuring brain activity.
Abstract: Bioremediative microorganisms comprising a 16S ribosomal subunit nucleic acid sequence and useful in various methods for dechlorinating chlorinated biphenyls (PCBs), including anaerobic dechlorination of ortho- and double-flanked chloro substituents of PCBs. The methods of bioremediation may employ consortia of microbially effective species, e.g., aerobic as well as anaerobic species, to dechlorinate corresponding PCB mixtures containing widely varying and significant numbers of PCB congeners.
Type:
Grant
Filed:
May 18, 2001
Date of Patent:
September 20, 2005
Assignees:
University of Maryland, Biotechnology Institute Medical University of South Carolina
Abstract: This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides. In one embodiment, the invention relates to non-natural amino acids that closely replicate the natural amino acids lysine and arginine.
Abstract: The present invention provides a method of identifying a human subject as having an increased likelihood of regulating blood pressure with dietary sodium intake, comprising determining the presence in the subject of a tissue kallikrein promoter allele genotype correlated with an increased likelihood of regulating blood pressure with dietary sodium intake, whereby the presence of the genotype identifies the subject as having an increased likelihood of regulating blood pressure by dietary sodium intake.
Abstract: This current invention includes compositions and methods of nitric oxide synthase inhibitors to treat or reduce ischemia/reperfusion injury in a patient. More specifically, the invention relates to a combinational therapy of 5-Aminoimidazole-4-carboxamide-1-B-D-ribonucleoside (AICAR) and N-acetyl cysteine (NAC) to attenuate ischemia/reperfusion injury to a transplanted organ.
Abstract: The present invention provides a method of identifying a human subject as having an increased likelihood of regulating blood pressure with dietary sodium intake, comprising determining the presence in the subject of a tissue kallikrein promoter allele genotype correlated with an increased likelihood of regulating blood pressure with dietary sodium intake, whereby the presence of the genotype identifies the subject as having an increased likelihood of regulating blood pressure by dietary sodium intake.
Abstract: The invention provides a method of screening for agents that promote or inhibit vasculogenesis or angiogenesis. The screening methods comprise culturing mesodermal stem cells, for example, allantoic cells; contacting the mesodermal stem cells with the agent to be screened; detecting endothelial cells or endothelial stem cells in the culture; and comparing the endothelial cells or endothelial cell precursors in the culture to be screened, with the endothelial cells or endothelial cell precursors in a control culture. An increase in endothelial cells or endothelial cell precursors in the culture to be screened indicates an agent that promotes vasculogenesis or angiogenesis. A decrease in endothelial cells or endothelial cell precursors in the culture to be screened indicates an agent that inhibits vasculogenesis or angiogenesis.
Type:
Application
Filed:
August 22, 2002
Publication date:
July 17, 2003
Applicant:
Medical University of South Carolina
Inventors:
Christopher J. Drake, W. Scott Argraves, Paul A. Fleming
Abstract: The invention provides compositions comprising the tissue specific and target RNA-specific ribozyme(s) in either a viral delivery system or a biologic liposome preparation, wherein the viral delivery system or a biologic liposome comprises a pathogen-specific promotor upstream from a sequence encoding a triple ribozyme comprising a) a 5′ autocatalytically cleaving ribozyme sequence, b) a catalytic ribozyme comprising a target RNA-specific binding site and c) a 3′ autocatalytically cleaving ribozyme sequence. The invention also provides methods of treating and/or preventing bacterial infections by administering the compositions of the invention.
Type:
Application
Filed:
April 19, 2002
Publication date:
July 3, 2003
Applicants:
Medical University of South Carolina, The Penn State Research Foundation, a Pennsylvania corporation
Inventors:
James S. Norris, Michael G. Schmidt, Joseph W. Dolan, Steven D. London, Harold D. May, Gary A. Clawson
Abstract: The present invention concerns a synthetic construct comprising a linear core chain having two or more side chains pending directly from different points on the linear core chain. Each of the side chains comprises an epitopic site of an antigen or a peptide. The synthetic constructs are monomeric units that can be linked together or polymerized to form a polymer. In this embodiment the epitopic sites of the side chains may be the same or different. The linear core chain may be a linear sequence of amino acids having two or more of the same peptide pending directly from different points on the linear sequence. Another aspect of the present invention concerns a support having one or more of the above synthetic constructs or polymers coupled thereto. Another embodiment of the present invention is directed to antibodies raised against the above synthetic constructs or polymers. The antibodies can be purified using the above mentioned supports.
Abstract: The present invention relates to multi-ribozymes and their use to target RNA in a tissue-specific, target RNA-specific, or pathogen-specific manner for the treatment of cancers, proliferative disease, and bacterial, parasitic and viral infections. More specifically, the present invention relates to the use of virions and viral vectors to package and deliver DNA encoding the multi-ribozymes to a host. The present invention relates to the use of liposomes and lipid-DNA complexes to deliver DNA encoding ribozymes to a host. Most specifically, the invention relates to the use of target specific virions to package and deliver DNA comprising a target specific promoter and encoding a ribozyme(s) directed to the target organism nucleic acids. The present invention further relates to a novel vectors encoding a multi-ribozyme structure with enhanced 5′ and/or 3′ autocatalytically cleaving ribozymes.
Type:
Application
Filed:
February 26, 2002
Publication date:
May 15, 2003
Applicant:
Medical University of South Carolina, an agency of the State of South Carolina
Inventors:
James S. Norris, Gary A. Clawson, Michael G. Schmidt, Brian Hoel, Wei-Hua Pan, Joseph W. Dolan, David Schofield, Caroline Westwater, Cancan Huang
Abstract: The current invention discloses novel methods for the inhibition of inducible nitric oxide synthesis (iNOS) and the production of NO. Methods of inhibiting the induction of proinflammatory cytokines are also described. Methods of treating various disease states, such as X-linked adrenoleukodystrophy, multiple sclerosis, Alzheimer's and septic shock using inhibitors of iNOS and cytokine induction are disclosed. The inhibitors include the exemplary compounds lovastatin, a sodium salt of phenylacetic acid (NaPA), FPT inhibitor II, N-acetyl cysteine (NAC), and cAMP. Methods of treating a nitric oxide or cytokine mediated disorder in a cell comprising administering a biologically effective amount of at least one induction suppressor of an inducible nitric oxide synthase or a cytokine is also described.
Type:
Grant
Filed:
May 25, 2000
Date of Patent:
January 28, 2003
Assignees:
Medical University of South Carolina, MUSC Foundation for Research Development
Abstract: This invention relates to positively charged non-natural amino acids, methods of making thereof, and utilization thereof in peptides. In one embodiment, the invention relates to non-natural amino acids that closely replicate the natural amino acids lysine and arginine.